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Vitiligo Autoantigen VIT75 Is Identified as Lamin A
in Vitiligo by Serological Proteome Analysis Based
on Mass Spectrometry
Qiang Li1, Yajie Lv1,4, Chunying Li1, Xiuli Yi1, Heather A. Long2, Hongjiang Qiao2, Tao Lu3, Qi Luan1,
Kai Li1, Xudong Wang1, Gang Wang1 and Tianwen Gao1
VIT75 is a 75-kDa melanocyte membrane antigen (Ag) that had been observed, but not identified until now.
Its immunopathogenic role in vitiligo remains unknown. In this study, serological proteome analysis based
on mass spectrometry was employed to identify VIT75. Three disparate 75-, 60-, and 45-kDa proteins on
two-dimensional (2D) gel were, respectively, identified as lamin A, tyrosinase-related protein 1, and melanin-
concentrating hormone receptor 1. The latter two proteins are well-known Ags. Immunoreactivity analysis
showed that the 75-kDa protein displayed on the 2D gel was recognized by human anti-lamin A IgG. Antibody
(Ab) reactivity to lamin A was positive in 28.6% of patients’ sera. Only 3.1% healthy sera reacted with the lamin A.
A total of 91.7% of the positive sera was from the active non-segmental vitiligo (NSV). The positive rate and mean
titer of anti-lamin A Ab are higher for NSV with autoimmune disease than for NSV without autoimmune disease.
These data demonstrate that VIT75 is lamin A. To our knowledge, this is a previously unreported vitiligo Ag. Anti-
lamin A Ab may be a potential marker of NSV with autoimmune disease. The study indicates that the targets of
autoantibodies in vitiligo patients can be revealed by serological proteome analysis.
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INTRODUCTION
Vitiligo is a disorder of pigmentation characterized by loss
of epidermal melanocytes (MC), which clinically results
in localized depigmentation of skin (Bor et al., 1969). Two
major clinical subtypes are distinguished, namely, segmental
vitiligo (SV), which follows dermatomal lines, and non-SV
(NSV), which includes generalized, symmetrical, and acro-
facial manifestations of the disease (Taieb, 2000). The
pathological mechanism has been unclear until now.
Currently, autoimmunity has been proposed as a critical
mechanism in MC destruction (Cunliffe et al., 1968; Hann
et al., 1993; Schallreuter et al., 1994; Ongenae et al., 2003;
Zettinig et al., 2003). Autoantibodies and autoreactive
CD8þ T cells that target MCs have been detected in most
vitiligo patients (Naughton et al., 1983; Le Poole et al., 1993).
They are demonstrated to contribute to the elimination of
MCs from the basal layer of the epidermis in vivo and in vitro
(Norris et al., 1988; van den Wijngaard et al., 2000). A wide
array of stress factors can provoke an autoimmune response
to MC, such as overexposure to UV (sunlight), contact with
bleaching phenols (4-tertiary butyl phenol), emotional stress,
mechanical injury (trauma and burn), and overexpression
of heat shock protein 70 (Barisic-Drusko and Rucevic, 2004;
Boissy and Manga, 2004; Namazi, 2007; Denman et al.,
2008). These stress factors can accelerate the depigmentation
that results from cytotoxicity to MCs. Stressed MCs were
found to mediate dendritic cell activation, antigen (Ag)
uptake, and the stimulation of T-cell immune response (Haug
et al., 2005; Kroll et al., 2005).
The first studies linking vitiligo to autoimmune response
involved the detection of serum autoantibodies in vitiligo
patients, with autoantibody levels found to be elevated in
patients with progressive vitiligo (Park et al., 1996; Kemp
et al., 1997b; Li et al., 2000; Lee and Yu, 2004). These
antibodies (Abs) mainly target MC Ags including melanoso-
mal membrane-fixed proteins, such as tyrosinase-related
proteins 1 and 2 (TYRP-1 and TYRP-2), some structural
melanosomal proteins (Kemp et al., 1997a; Kemp et al.,
1998a; Kemp et al., 1998b, 1999; Okamoto et al., 1998;
Palermo et al., 2001), and a 75-kDa membrane protein that
had been previously observed but not identified, and named
VIT75 (Cui et al., 1992; Cui et al., 1995). Recently, Kemp
et al. (2002) found a, to our knowledge, previously
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unreported, plasma membrane Ag, which they called
melanin-concentrating hormone receptor 1 (MCHR-1), that
is involved in cAMP regulation. Although it remains unclear as
to whether the specific antibodies to pigment cells or secondary
antibodies are pathogenic, the identification and characteriza-
tion of the autoantigens may open the way for uncovering the
pathogenic mechanism and formation of autoantibodies.
Through preliminary studies, we also observed that the VIT75
of MCs reacted with patient serum Abs; however, VIT75 has not
been identified until now.
This study aims to identify VIT75, the vitiligo-associated
autoantigen of epidermal MC. Serological proteome analysis
is powerful tool for the identification of a large group of
candidate cancer biomarkers recognized as autoantigens by
the sera of cancer patients (Klade et al., 2001). We used
serological proteome analysis to demonstrate that VIT75 is
lamin A.
RESULTS
Characterization of vitiligo sera against MC membrane proteins
To assess immunoreactivity of vitiligo sera to MC membrane
proteins, we performed ELISA assay on 300 sera using two
Abs against human IgG and IgM as secondary antibodies.
Anti-MC Abs of IgG isotype were detected in 158 of 256
(61.7%) sera from NSV patients, including 126 active and
32 inactive patients. Significant differences were seen in
the positive rate of anti-MC Ab between the active NSV and
the inactive NSV (74.6% (126/169) versus 36.8% (32/87);
Po0.01; Figure 1a). A total of 10 SV sera (8 active and
2 inactive) were found to have anti-MC Abs and in 44 SV
sera, no significant differences were seen in disease activity of
the SV group (active versus inactive: 23.5% (8/34) versus
20.0% (2/10); P40.05). The prevalence of anti-MC Abs
was significantly lower in SV patients than in NSV patients
(22.7 versus 61.7%). Moreover, the positive rate for the anti-
MC Ab IgM isotype was significantly lower than that that
for the IgG isotype in NSV patients (32.0% (82/256) versus
61.7% (158/256); Po0.01). There was no apparent asso-
ciation between reactivity of the Ab IgM and disease sub-
type and activity either in the NSV or the SV patient group.
These data suggest that the anti-MC membrane protein
IgG (not IgM) is the main antibody isotype associated with
disease activity.
Next, sera with a high antibody titer of greater than 1:128
from 62 patients were used for analyzing the reactivity with
MC membrane proteins. Details of the 62 patients are
summarized in Supplementary Table S1 online. The repre-
sentative pattern of reactivity is shown in Figure 1b. These
sera recognized the 83-kDa (G1); 75-kDa (B1, C1, F1); 55- to
60-kDa (A1, D1, G2, H1, J1); 40- to 45-kDa (A2, B2, B3, C2,
D2, E1, F2); and 35- to 37-kDa (A3, B4, H2, I1) protein bands
in western blot assays using total MC membrane proteins.
The overall positive rate was 91.9% (57 of 62). There are 185
positive bands. They obviously exceed those (rate: 12.5% and
amount of bands: 11) in the 64 normal sera group. These
bands seem to have no correlation with disease subtype or
activity. The protein band of 75 kDa was recognized by 28 of
62 (45.2%) of the patients’ sera.
Mass spectrometry and immunoblotting for identification
of VIT75
The MC membrane proteins were segregated on two-
dimensional (2D) gel and then immunoblotted by the vitiligo
Abs that were purified from anti-75 kDa protein sera from 28
patients by protein-G column, with 14 normal sera used as
the negative control. Details of the 28 patients are summar-
ized in Supplementary Table S1 online. The prevalence rate
of autoimmune disease was significantly higher in these 28
patients than in the 62 patients whose sera were used for
analyzing the reactivity with total MC membrane proteins
(35.7 versus 19.4%; Po0.05). By high-speed centrifugation,
350mg of protein was extracted from the cellular membrane
fraction of 3107 MCs and was mainly centralized at
isoelectric point 4.5–9.0 (Figure 2a). Immunoblots using sera
with Abs against 75-kDa protein showed 14 positive proteins:
3 disparate and 11 co-displaying protein points (Figure 2b).
Details of the 14 positive spots are summarized in Table 1.
After matrix-assisted laser adsorption/ionization time-of-flight
mass spectrometry analysis, spot 1 (molecular weight 75 kDa;
isoelectric point 6.4) was identified as lamin A through
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Figure 1. Characterization of patient anti-melanocyte (MC) sera. (a) ELISA
analysis of reactivity of the sera with MC membrane protein. Healthy sera
were the negative control. The positive rates (percent, %) of anti-MC sera
(1:40) are significantly higher for active non-segmental vitiligo (NSV) than for
inactive NSV. No significant difference is seen between active segmental
vitiligo (SV) and inactive SV. (b) Characterization of MC membrane protein
recognized by vitiligo (n¼ 62) and normal sera (n¼64) (1:40). The molecular
weights (MWs) are as follows: 83 kDa for band G1; 75 kDa for B1, C1, and F1;
55–60 kDa for A1, D1, G2, H1, and J1; 40–45 kDa for A2, B2, B3, C2, D2, E1,
and F2; and 35–37 kDa for A3, B4, H2, and I1.
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database search with peptide mass fingerprint, the protein
score was found to be significant (Po0.05), and the sequence
coverage (matched peptides) reached 40 with difference
between measured and calculated masses below 0.1 Da.
Peptide mass fingerprint analysis was made for at least three
samples from three independent experiments. Spots 2 and 3
were TYRP-1 and MCHR-1, respectively, with the same criteria
of acceptance. TYRP-1 is a well-known vitiligo Ag; MCHR-1 is
a, to our knowledge, previously unreported, plasma membrane
Ag associated with vitiligo (Kemp et al., 2002).
Quadrupole/time-of-flight analysis showed that the pro-
tein-1 sequence (TLEGELHDLR) of precursor at m/z 1035.49
9.08.07.06.05.0
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Figure 2. Differential displaying two-dimensional (2D) western blot of melanocyte (MC) membrane proteins. (a) Silver staining of MC membrane
proteins separated by 2D western blotting (isoelectric point (pI) 4.5–9.0). Western blot shows that 3 out of 14 proteins (spots 1, 2, and 3) reacted with the
vitiligo IgG (1:1,000) from 28 patient sera (mixed equally) (b), but not with the sera of healthy control IgG (1:1,000) (c). Molecular weight and pI of the
14 proteins are listed in Table 1.
Table 1. The 14 proteins that reacted with vitiligo Abs, as identified by MS
Theoretical
Spot ID1 Protein identity
Accession
number MW pI
Sequence
coverage
(%)2 Score3
Matched/
searched
Unique
peptides
detected
1 Lamin A gi|57014047 74026 6.44 39 189 17/24 5
2 Tyrosinase-related protein 1 gi|12644141 59609.0 5.52 39 140 11/14 4
3 Melanin-concentrating hormone receptor 1 gi|33860175 45962 9.23 37 227 11/11 10
4 Mitochondrial inner-membrane protein (Mitofilin) gi|5803115 83677.91 6.08 27 210 15/17 12
5 Lysosome-associated membrane glycoprotein 1 precursor gi|126376 44773.01 9.22 23 147 15/16 3
6 Keratin, type II cytoskeletal 8 (cytokeratin-8) gi|90110027 53704.25 5.52 43 115 15/29 6
7 ADAM 15 precursor gi|29337230 87717.16 6.03 26 269 22/28 4
8 Cytochrome P450 11B1 gi|19856290 57528.92 9.27 16 146 13/17 3
9 Transmembrane BAX inhibitor motif-containing protein 2 gi|38503167 35109.72 6.06 49 206 10/10 8
10 Zinc finger protein-like 1 gi|6649925 34113.99 8.42 40 151 11/20 5
11 Translocation-associated membrane protein 1-like 1 gi|119626717 39573.67 8.29 27 197 14/19 10
12 Syntaxin-binding protein 4 gi|74749713 61760.94 5.16 50 210 18/24 9
13 Tetraspanin-12 gi|11135167 35382.56 5.72 37 191 14/20 2
14 Heterogeneous nuclear ribonucleoprotein H3 gi|24981041 36926.49 6.37 44 254 15/22 12
Abbreviations: Abs, antibodies; MS, mass spectrometry; MW, molecular weight; pI, isoelectric point.
1The spot ID is the number of the significantly stained proteins in Figure 2a.
2Ideally, sequence coverage (%) means the number of amino acids spanned by the assigned peptides divided by the sequence length. A coverage ratio
exceeding 30% is the baseline of availability for inclusion.
3Acceptance criterion, mascot protein search score X35, was regarded as significant with Po0.05.
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was consistent with the sequence of Q5I6Y6_HUMAN
lamin A through NCBI BLAST (score¼35.0; z¼ 1; criteria
for inclusion: ion scoreX35; mass numbers matched and not
matched were 4 and 11). The sequences of proteins 2 and 3
(NISIYNYFV and HWCNNVPD) were consistent with pro-
teins TYRP-1 and MCHR-1 under the same criteria.
Verification assay of VIT75, TYRP-1, and MCHR-1
To confirm three proteins, 2D western blot was performed
with rabbit anti-lamin A, TYRP-1, and MCHR-1 antibodies
generated by immunization. These three polyclonal Abs
(1:2,000) bound to the protein spots 1, 2, and 3 of 2D gel, the
negative control (normal rabbit Abs) showed no reactivity
(Figure 3a). To determine immunoreactivity with the lamin A of
vitiligo sera, we performed western blot with the recombinant
lamin A and patients’ sera (n¼84). It was shown that 28.6%
(24/84) of patient sera recognized lamin A, 3.1% (2/64) healthy
sera reacted with lamin A, and 9.5% (8/84) and 14.3% (12/84)
of vitiligo sera were against TYRP-1 and MCHR-1, respectively
(Figure 3b). Indirect immunofluorescence assay showed that the
vitiligo sera Abs positively stained the nuclear membrane of
MCs, which also reacted with anti-lamin A Ab. Normal human
sera Abs presented negative staining at the nuclear membrane
containing lamin A proteins (Figure 3c).
Analysis of Ab reactivity to lamin A in vitiligo patients
Details of the 84 patients whose sera were used for analyzing
Ab reactivity to lamin A are summarized in Table 2. They
include 24 positive and 60 negative sera to lamin A. In
contrast, there was apparent correlation between the Ab
reactivity and the disease activity, subtype, involved area of
lesion, family history, and the prevalence of autoimmune
disorder. A total of 91.7% (22 of 24) of sera were from patients
with active vitiligo in the Ab-positive group, but only 8.3% of
sera were from the inactive vitiligo. A total of 68.3% (41 of 60)
of active vitiligo was shown in the Ab-negative group. Mean
area of lesion is obviously larger in the Ab-positive group than
in the Ab-negative group (mean ratio of lesion area to whole
body surface area: 23:12%; Po0.05 ). All 24 patients with the
anti-lamin A Ab have NSV. The prevalence rate of auto-
immune disease was increased in the group in which Abs were
positive to lamin A. The analysis is detailed in Table 3.
Interestingly, we found the occurrence rate of vitiligo to be
significantly higher in first-degree relatives of the positive Ab
group than in those of the negative Ab group (12.5 versus
6.7%; Po0.05; Table 2). There is no obvious association
between the Ab reactivity and the patient sex, age, age at onset
of disease, disease duration, clinical manifestations of NSV, or
inducing factors (Table 2).
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Figure 3. Validation assay of lamin A, tyrosinase-related protein 1 (TYRP-1), and melanin-concentrating hormone receptor 1 (MCHR-1). (a) Two-dimensional
(2D) western blot showed that spots 1, 2, and 3 are targeted by three rabbit anti-rlamin A, rMCHR-1, and rTYRP-1 antibodies (Abs; 1:2,000) but not by normal
Abs (1:2,000). Anti-keratin 8 Ab was the positive control. (b) Western blot (1D) shows that the three glutathione-S-transferase (GST; 29 kDa) fusion proteins
reacted with vitiligo Abs (1:40) but not with normal Abs (1:40). The three rabbit Abs and GST Abs were positive controls (1:1,000). (c) Immunocytochemistry
assay shows that the human anti-lamin A vitiligo Ab (fluorescein isothiocyanate, green) deposits at the nuclear membrane. Mouse anti-lamin A Ab (1:1,000) was
the positive control and normal Ab (1:40) was the negative control. The cell nucleus (blue) was counterstained by 40,6-diamidino-2-phenylindole (DAPI).
Bar¼10 mm. MC, melanocyte; MW, molecular weight; pI, isoelectric point.
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Our overall analysis of Ab reactivity to lamin A in vitiligo
patients and control groups is shown in Table 3. The Ab
reactivity was detected in 24 of 72 (33.3%) sera in the case of
NSV, but only in 2 of 64 controls and in 0 of 12 patients with
SV. In NSV with versus without autoimmune disease, the
humoral immune response to lamin A was demonstrated in 5
of the 11 (45.5%) individuals and in 9 of the 61 (14.8%)
individuals, respectively. A significant difference in preva-
lence of immunoreactivity in the control and the patients was
evident only in the NSV patient group. The prevalence of Ab
reactivity was also elevated significantly in the NSV patient
groups (with or without autoimmune disease) when com-
pared with control (Po0.005; Table 3). The Ab reactivity
was highly increased for NSV with autoimmune disease
compared with those without autoimmune diseases, and
there was a significant difference (Po0.05; Table 3). No
obvious relationship was observed between reactivity of the
Ab and the type of autoimmune disease, because of the small
sample size.
To further determine whether the intensity of anti-lamin A
immune response differs with disease activity, subtype, and
accompanying autoimmune disease, the highest-dilution
titers of anti-lamin A Ab IgG were determined for all 24
positive sera by ELISA. As shown in Supplementary Figure S1
online, IgG titers ofX1:128 were observed only in sera from
eight vitiligo patients with autoimmune disease, including
three chronic autoimmune hepatitis, two rheumatoid arthri-
tis, one autoimmune thyroiditis and two systemic lupus
erythematosus (SLE). The mean titer of Ab IgG is lower for the
inactive sera than for the active sera (1:4 versus 1:96). The
mean titer of Ab IgM did not differ significantly among these
groups (data not shown). The mean titers of either IgM (1:8) or
IgG (1:24) isotypes were higher for the vitiligo group than for
the healthy group (1:2; n¼2), although no significant
difference was observed, because of the small sample size.
DISCUSSION
In this study, unknown Ag VIT75 was identified as membrane
protein lamin A by serological proteome analysis; in all,
28.6% of patients’ sera recognized lamin A and the level of
human anti-lamin A Abs obviously paralleled the disease
activity. Anti-lamin A, B1, A/C, and ABC autoantibodies have
been frequently reported in most sera from patients with
autoimmune diseases, including SLE, chronic autoimmune
hepatitis, rheumatoid arthritis, linear scleroderma, and
autoimmune cytopenias (McKeon et al., 1983; Wesierska-
Gadek et al., 1988; Senecal et al., 1999; Coppo et al., 2004).
Although these Abs to lamins have no disease specificity,
high titers of IgG anti-lamin B1 autoantibodies are highly
Table 3. Reactivity of anti-lamin A IgG in vitiligo patients and controls
Antibody
reactivity
Controls
(n=64)
NSV
(n=72) P-value1 SV (n=12) P-value1
NSV without
autoimmune
disease (n=61) P-value1
NSV with
autoimmune
disease (n=11) P-value1 P-value2
Negative 62 (96.9%) 48 (66.7%) 7.76106*** 12 (100%) 0.535 52 (85.3%) 0.022* 6 (54.5%) 0.018* 0.016*
Positive 2 (3.1%) 24 (33.3%) 0 (0%) 9 (14.8%) 5 (45.5%)
Abbreviations: NSV, non-segmental vitiligo; SV, segmental vitiligo.
1P-value calculated using Pearson w2-test for comparing the prevalence of antibody reactivity in vitiligo patients and controls.
2P-value indicating NSV with autoimmune disease versus NSV without autoimmune disease.
*Po0.05 and ***Po0.005 were considered significant.
Table 2. Comparison of NSV patients with and
without immunoreactivity to lamin A
Patients with
immunoreactivity
(n=24)
Patients without
immunoreactivity
(n=60)
Sex (male/female), n 14/12 37/23
Mean age (range), years 19.5 (13–32) 26.3 (11–54)
Mean age at onset of vitiligo
(range), years
16.0 (11–36) 32.1 (9–48)
Mean disease duration
(range), years
5.1 (0.2–12) 13 (0.1–33)
Mean ratio of lesion area to
body surface area (range), %
23 (1–50) 12 (1–60)
Disease activity (inactive/
active phase), n
2/22 19/41
SV, n 0 12
Clinical manifestation of
NSV, n
24 48
Generalized 10 17
Symmetrical 8 15
Acrofacial 6 16
Autoimmune disease, % (n) 37.5 (9/24) 3.3 (2/60)
Family history,1 % (n) 12.5 (3/24) 6.7 (4/60)
Disease-inducing factors, n 6 7
Mental stress 2 4
Overexposure to sunlight 1 2
Contact with bleach
phenol
1 0
Trauma 1 0
Isomorphic response 1 1
Abbreviations: NSV, non-segmental vitiligo; SV, segmental vitiligo.
1Includes only the first-degree relatives.
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specific for a subset of SLE patients whose clinical character-
istics include lupus anticoagulant and other laboratory
manifestations of antiphospholipid syndrome (Senecal et al.,
1999). Interestingly, half of the vitiligo patients with Ab to
lamin A had at least one autoimmune disorder; the
prevalence rate and titers of Ab exceed those of patients
without autoimmune disease or healthy controls. This
suggests that anti-lamin A Ab is likely to be a marker of
vitiligo with autoimmune disease. These, to our knowledge,
previously unreported, findings further support the involve-
ment of a systemic autoimmune mechanism in the pathogen-
esis of vitiligo.
Lamin A is a type V intermediate filament protein that is a
major component of nuclear lamina. Although anti-lamin
antibodies (ALAs) are detected in sera in a range of
autoimmune diseases (Nesher et al., 2001), the process
whereby ALAs are induced in vivo remains unknown. There
are two hypotheses about the origin of ALAs. One hypothesis
is that many ALAs are ‘‘natural’’ antibodies, that is, antibodies
that are present in the serum of healthy individuals and that
are reactive with autoantigens in the absence of previous
apparent specific antigenic contact. In this study, Abs against
lamin A have also been detected in normal sera, although the
reactivity frequency is obviously lower than in vitiligo sera.
Anti-lamin A Ab isotypes also include IgG and IgM. These are
consistent with the fundamental characters of the natural
antibody. Another hypothesis is that the origin of ALAs relates
to apoptosis in epidermal MCs. It has been demonstrated that
lamins redistribute from nuclear lamina to apoptotic blebs
during apoptosis in endothelial cells for SLE. A new model
that is used for illustrating the relationship between humoral
response to lamin A and apoptosis in MC is proposed in
Supplementary Figure S2 online. It is helpful for clearly and
visually elucidating the pathways that may be involved in
destruction and presentation of MCs.
The role of autoantibodies in the destruction of epidermal
MCs remains unknown. Previous studies showed low
immunoreactivity of vitiligo autoantibodies such as anti-
tyrosinase Ab (11%) (Kemp et al., 1997a), anti-TYRP-2 Ab
(5%) (Kemp et al., 1997b), anti-Pmel17 Ab (5%) (Kemp et al.,
1998a), anti-transcription factor SOX110 (3%) (Hedstrand
et al., 2001), anti-MCHR-1Ab(16.4%) (Kemp et al., 2002),
and anti-TYRP-1 Ab (5.7%) (Kemp et al., 1998b). Recently,
Waterman et al. found several, to our knowledge, previously
unreported, autoantigens (for example, g-enolase, a-enolase,
translation-initiation factor 2, heat shock protein 90, osteo-
pontin, ubiquitin-conjugating enzyme, GTP-binding protein,
and Rab38) by the serological selection of phage-displayed
MC cDNA expression library. All these Ags showed the
reactivity with vitiligo patient sera, ranging from 6 to 15%
(Waterman et al., 2010). Likewise, this study indicates that
the individual recognition rates are also not high in the
vitiligo sera targeting these proteins, including lamin A
(28.6%), MCHR-1 (14.3%), and TYRP-1 (9.5%). The low
prevalence of different Abs may indicate that vitiligo
represents a spectrum of disease pathologies that lead to
similar clinical manifestations rather than it being a disorder
with a single pathogenicity. Moreover, most patients with
anti-MC Abs are in the active phase and the IgM subclass was
also detected in sera, which suggests that these released Ags
elicited humoral response in the early phase of the disorder.
In conclusion, this study identified VIT75 as lamin A in
epidermal MCs. Anti-lamin A Ab has the potential to be an
important autoantibody in a subset of NSV with autoimmune
disease. Ab examination may predict whether a patient has
accompanying autoimmune disease(s) and the possibility of
developing an autoimmune disease. These findings further
support the idea that an autoimmune mechanism has a role in
the development of vitiligo.
MATERIALS AND METHODS
Patients and sera
Serum samples were obtained from vitiligo patients (n¼ 300; 135
male, 165 female; mean age: 25 years; age range: 12–56 years) who
visited the Xijing Hospital in China from 2002 to 2006. Of these
patients, 44 were diagnosed with SV (unilaterally distributed
lesions), 256 with NSV (generalized, symmetrical, and acrofacial
lesions), 203 with active vitiligo (slowly progressing, enlarging, or
recurring), and 97 with inactive vitiligo (relatively stable for least 6
months). A total of 257 patients had no other autoimmune disorders
and/or family history. In total, 43 had at least one other autoimmune
disorder (Graves’ disease, rheumatoid arthritis, autoimmune thyr-
oiditis, chronic autoimmune hepatitis, diabetes mellitus, SLE, linear
scleroderma, autoimmune cytopenias, connective tissue disease, or
alopecia areata). In all, 64 sera from healthy subjects (41 male, 23
female; age range: 21–59 years; mean age: 34 years) were used as
normal controls. This study was approved by the Ethics Committee
of the Fourth Military Medical University (Shaanxi, China) and all
subjects gave informed consent. The study was approved by the
institutional review board and the Declaration of Helsinki protocols
were followed.
MC membrane sample preparation
Primary MCs were isolated from circumcised foreskin of healthy
adults, as described by Eisinger and Marko (1982). MC membrane
lysates were prepared for 1D and/or 2D electrophoresis and western
blot. Briefly, 3 107 fourth to sixth passage MCs were resuspended
in 35-ml buffer (50mM Tris (pH 8.0), 150mM NaCl, 5mM MgCl2)
and sonicated on ice for 15minutes at 50% power and five duty
cycles in a Branson Sonifier (BD Biosciences, San Diego, CA). The
membrane extract was collected by centrifugation at 40,000 g,
resuspended in an equal volume buffer and 2% sodium lauroyl
sarcosinate, and then incubated at 37 1C for 1 hour to facilitate inner
membrane solubilization. The MC membrane lysate was pelleted
at 40,000 g, washed with buffer, and stored at 70 1C. Outer
membrane extracts were prepared with protease inhibitor. A total of
5 and 1mM tosyl-L-lysine chloromethyl ketone were, respectively,
used for cell harvesting and dissolution.
2D electrophoresis and immunoblot
Gradient pH 4–7, 10 linear and pH 3–10 nonlinear immobiline dry
strips (Pharmacia Biotech, Uppsala, Sweden) were used for iso-
electric focusing. After rehydration in a polyacrylic tray overnight,
each strip was soaked in 300ml MC sample solution diluted to an
appropriate protein concentration with lysis buffer. Focusing was
carried out for 26 hours at 20 1C, 2mA, and 5W maximum, to a total
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of 49,950V hours with a Multiphor II (Pharmacia Biotech). For the
second dimension, SDS-PAGE strips were equilibrated using a two-
step procedure, each for 10minutes, in 10ml of 6M urea, 30% (w/v)
glycerol, 2% (w/v) SDS, 50mm Tris (pH 8.8), and a trace of
bromophenol blue. Electrophoresis was carried out at 4 1C in Hoeffer
600 SE units (Bio-Rad, Richmond, CA) for 1 hour at 20mA per gel
followed by 4 hour at 40mA per gel. Gels were stained with Novex
Colloidal Coomassie Blue Staining Kit (Invitrogen, Carlsbad, CA)
according to manufacturer protocols or by using fast, acidic silver
staining. For hybridization with antibodies, the proteins separated in
2D electrophoresis were transferred onto polyvinylidene difluoride
membrane (Bio-Rad) and incubated with purified vitiligo serum IgG
(1:1,000); healthy serum IgG (1:1,000) was used as a control. The 2D
western blot was repeated three times.
Mass spectrometry
Excised proteins were digested as described previously (Gharahda-
ghi et al., 1999). Protein identification was performed on the matrix-
assisted laser adsorption/ionization time-of-flight mass spectrometer
by 4700 Proteomics Analyzer (Applied Biosystems, Foster, CA) at the
National Center of Biomedical Analysis, Beijing, China. The protein
identification was reconfirmed by a Q-TOF micromass spectrometer
(Waters, Milford, MA). The obtained peptide mass fingerprint was
used to search through the Swiss-Prot human protein databases
MSDB 20060831 (3,239,079 sequences; 1,079,594,700 residues)
and the National Center for Biotechnology Information Non-redun-
dant Human Protein Databases (NCBInr 20060211), using the Mascot
Program Engine (version 1.9; Matrix Science, London, UK). All the
automatic data analyses and database searches were completed by
GPS Explorer software (version 3.6; Applied Biosystems).
Recombinant protein generation
Explained in Supplementary Materials and Methods online.
Rabbit polyclonal Ab production
Explained in Supplementary Materials and Methods online.
Questionnaire
Explained in Supplementary Materials and Methods online.
Statistical analysis
Data were reported as mean values and/or percentages. We
determined statistical significance using Student’s t-test or Pearson
w2-test. A P-value o0.05, 0.01, or 0.005 was considered as
statistically significant. Analysis was carried out by the statistical
software SPSS 10.0 (SPSS, Chicago, IL).
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